| Bioactivity | ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibitor of apoptosis protein (XIAP). | ||||||||||||
| Invitro | ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP, currently being investigated in a single-agent Phase 1/2 clinical trial in patients with advanced solid tumors and lymphomas. Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660[1]. | ||||||||||||
| Name | ASTX660 | ||||||||||||
| CAS | 1799328-86-1 | ||||||||||||
| Formula | C30H42FN5O3 | ||||||||||||
| Molar Mass | 539.68 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
ASTX660
CAS: 1799328-86-1 F: C30H42FN5O3 W: 539.68
ASTX660 is an orally bioavailable dual antagonist of cellular inhibitor of apoptosis protein (cIAP) and X-linked inhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.